GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hansoh Pharmaceutical Group Co Ltd (HKSE:03692) » Definitions » 3-Year FCF Growth Rate

Hansoh Pharmaceutical Group Co (HKSE:03692) 3-Year FCF Growth Rate : -6.00% (As of Jun. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Hansoh Pharmaceutical Group Co 3-Year FCF Growth Rate?

Hansoh Pharmaceutical Group Co's Free Cash Flow per Share for the six months ended in Jun. 2023 was HK$0.18.

During the past 12 months, Hansoh Pharmaceutical Group Co's average Free Cash Flow per Share Growth Rate was -40.40% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -6.00% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 9.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 8 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Hansoh Pharmaceutical Group Co was 42.70% per year. The lowest was -6.80% per year. And the median was 1.50% per year.


Competitive Comparison of Hansoh Pharmaceutical Group Co's 3-Year FCF Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansoh Pharmaceutical Group Co's 3-Year FCF Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Hansoh Pharmaceutical Group Co's 3-Year FCF Growth Rate falls into.



Hansoh Pharmaceutical Group Co 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Hansoh Pharmaceutical Group Co  (HKSE:03692) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Hansoh Pharmaceutical Group Co 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Hansoh Pharmaceutical Group Co's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Hansoh Pharmaceutical Group Co (HKSE:03692) Business Description

Traded in Other Exchanges
Address
287 Xiangke Road, Pudong New District, Shanghai, CHN, 201210
Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.

Hansoh Pharmaceutical Group Co (HKSE:03692) Headlines

No Headlines